Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (284)	6/3/1999 12:31:00 PM
From: scaram(o)uche	Respond to of 1475

Dalroi: One can say, without exageration, that the allotransplantation market is huge and barely penetrated. I hope that AlloMune will allow for further penetration of the market and capture of much of the existing market. Microcap, large percentage of market cap is cash Potential leverage with MEDI collaboration, although other companies (anti-CD40L and CTLA4) seem to be making MEDI look like a non-committed snail, and there is a continuous [relative] paucity of references that cite CD2 and tolerance. Potential leverage with xenotransplantation (Novartis) Potential leverage with graft-versus-leukemia (lymphoid malignancies, in general) Rick